Lupin has informed that it enclosed a Press Release as regards, receipt of Establishment Inspection Report from the US FDA for the Company’s Pithampur Unit-2 manufacturing facility which manufactures oral solids and ophthalmic dosage forms. This is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
